Genmab A/S (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Separately, J P Morgan Chase & Co cut Genmab A/S from an “overweight” rating to a “neutral” rating in a research note on Friday, October 6th.
Shares of Genmab A/S (OTCMKTS:GNMSF) opened at $179.50 on Monday. The firm has a market capitalization of $11,025.07, a PE ratio of 62.63 and a beta of 1.01. Genmab A/S has a twelve month low of $159.25 and a twelve month high of $239.75.
COPYRIGHT VIOLATION WARNING: “Genmab A/S (GNMSF) Stock Rating Lowered by Zacks Investment Research” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://sportsperspectives.com/2017/11/15/genmab-as-gnmsf-stock-rating-lowered-by-zacks-investment-research.html.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.